APRE (Aprea Therapeutics) ROE % Adjusted to Book Value: -221.27% (As of Mar. 2026)


APRE Aprea Therapeutics Inc APRE
30 GF Score
Price $0.81
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics ROE % Adjusted to Book Value?

Aprea Therapeutics APRE -1.67% 30 ROE % Adjusted to Book Value is -221.27% as of Mar. 2026. GuruFocus rates APRE with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Aprea Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -48.68%. Aprea Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 0.22. Aprea Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -221.27%.

Aprea Therapeutics ROE % Adjusted to Book Value Related Terms

Aprea Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics ROE % Adjusted to Book Value Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only -46.07 -434.54 -64.50 -76.86 -141.73

Aprea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -125.38 -124.25 -120.65 -150.23 -221.27

APRE vs JUNS, KAPA, GOVX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Aprea Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprea Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprea Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aprea Therapeutics's ROE % Adjusted to Book Value falls into.


APRE
30GF Score
Aprea Therapeutics Inc APRE
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics ROE % Adjusted to Book Value Calculation

Aprea Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-79.37% / 0.56
=-141.73%

Aprea Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-48.68% / 0.22
=-221.27%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -221.27% mean?
Aprea Therapeutics (APRE) has a ROE % Adjusted to Book Value of -221.27% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aprea Therapeutics and its competitors.
Is Aprea Therapeutics' ROE % Adjusted to Book Value too high?
Aprea Therapeutics' current ROE % Adjusted to Book Value is -221.27%. Overall, Aprea Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' ROE % Adjusted to Book Value compare to JUNS and KAPA?
Aprea Therapeutics' ROE % Adjusted to Book Value of -221.27% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aprea Therapeutics and its competitors. Aprea Therapeutics's current ROE % Adjusted to Book Value is -221.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current ROE % Adjusted to Book Value of -221.27%. The current ROE % Adjusted to Book Value is -221.27%. Aprea Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current ROE % Adjusted to Book Value is -221.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
30GF Score

Get the complete analysis for APRE

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.81
Price